Anika Therapeutics, Inc. revised revenue guidance for the fiscal year 2023. For the year, the company raised its overall revenue outlook to be between $164 million to $166 million, representing growth of 5% to 6% compared to 2022, up from its previous range of $159.5 million to $163 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.63 USD | +1.46% | -7.10% | +13.11% |
05-08 | Transcript : Anika Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q1 EPS $0.09 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.11% | 380M | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-41.29% | 11.89B | |
-15.50% | 11.91B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- ANIK Stock
- News Anika Therapeutics, Inc.
- Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023